Perspective Therapeutics Files DEF 14A for 2024
Ticker: CATX · Form: DEF 14A · Filed: Apr 16, 2025 · CIK: 728387
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
TL;DR
Perspective Therapeutics (fka Isoray) filed its 2024 DEF 14A detailing exec comp & equity awards for Johan Spoor & Lori Woods.
AI Summary
Perspective Therapeutics, Inc. (formerly Isoray, Inc.) filed a DEF 14A on April 16, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key individuals mentioned in relation to equity awards include Johan Thijs Spoor and Lori A. Woods, with specific vesting dates for equity awards granted in covered years such as 2023 and 2024.
Why It Matters
This filing provides insight into how Perspective Therapeutics compensates its top executives, which can influence investor decisions and the company's strategic direction.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) detailing executive compensation and corporate governance, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Perspective Therapeutics, Inc. (company) — Filer
- Isoray, Inc. (company) — Former Company Name
- Johan Thijs Spoor (person) — Executive/Director mentioned in equity awards
- Lori A. Woods (person) — Executive/Director mentioned in equity awards
- 2024-12-31 (date) — Fiscal Year End
- 20250416 (date) — Filing Date
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for their annual or special meetings. It provides detailed information on matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
When did Perspective Therapeutics, Inc. change its name from Isoray, Inc.?
Perspective Therapeutics, Inc. changed its name from Isoray, Inc. on December 31, 2018.
Who are the key individuals mentioned in relation to equity awards for the covered years?
Johan Thijs Spoor and Lori A. Woods are mentioned in relation to equity awards granted and vested in covered years, with specific dates provided for their vesting periods.
What is the fiscal year end for Perspective Therapeutics, Inc. as reported in this filing?
The fiscal year end for Perspective Therapeutics, Inc. is December 31, as indicated by the 'FISCAL YEAR END: 1231' data point.
What is the filing date of this DEF 14A?
This DEF 14A filing was made on April 16, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 16, 2025 by Johan Thijs Spoor regarding Perspective Therapeutics, Inc. (CATX).